Related Experiment Video
Updated: May 27, 2026

Touchscreen Sustained Attention Task (SAT) for Rats
Published on: September 15, 2017
Deficits in attentional control: cholinergic mechanisms and circuitry-based treatment approaches
Martin Sarter1, Giovanna Paolone
1Department of Psychology, University of Michigan, Ann Arbor, MI 48103-8862, USA. msarter@umich.edu
Abstract:
The cognitive control of attention involves maintaining task rules in working memory (or "online"), monitoring reward and error rates, filtering distractors, and suppressing prepotent, and competitive responses. Weak attentional control increases distractibility and causes attentional lapses, impulsivity, and attentional fatigue. Levels of tonic cholinergic activity (changes over tens of seconds or minutes) modulate cortical circuitry as a function of the demands on cognitive control. Increased cholinergic modulation enhances the representation of cues, by augmenting cue-evoked activity in thalamic glutamatergic afferents, thereby increasing the rate of detection. Such cholinergic modulation is mediated primarily via α4β2* nicotinic acetylcholine receptors. Animal experiments and clinical trials in adult patients with ADHD indicate that attentional symptoms and disorders may benefit from drugs that stimulate this receptor. Tonic cholinergic modulation of cue-evoked glutamatergic transients in prefrontal regions is an essential component of the brain's executive circuitry. This circuitry model guides the development of treatments of deficits in attentional control.
More Related Videos
09:37Measurement of Neurophysiological Signals of Ignoring and Attending Processes in Attention Control
Published on: July 5, 2015
10:02Event Related Potentials (ERPs) and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder (ADHD)
Published on: March 12, 2020
Related Concept Videos
Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
Alzheimer's Disease: Treatment
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Direct-Acting Cholinergic Agonists: Pharmacokinetics
Direct-Acting Cholinergic Agonists: Therapeutic Uses